Who
K. Angela Macfarlane
Director
Company insider
Files Form 4 as: Director, RenovoRx.
In numbers
- Trades disclosed
- 9
- Buys
- 1
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 1 Oct 2021
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,924 at $0.00 | filing |
| 1 Oct 2025filed 2 Oct 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,640 at $0.00 | filing |
| 1 Oct 2024filed 2 Oct 2024 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,099 at $0.00 | filing |
| 26 Jan 2024filed 30 Jan 2024 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code P | —40,983 | filing |
| 26 Jan 2024filed 30 Jan 2024 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | —40,983 | filing |
| 1 Oct 2023filed 2 Oct 2023 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,099 at $0.00 | filing |
| 1 Oct 2022filed 4 Oct 2022 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,099 at $0.00 | filing |
| 10 Mar 2022filed 14 Mar 2022 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,582 at $0.00 | filing |
| 1 Oct 2021filed 5 Oct 2021 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,154 at $0.00 | filing |
News
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP TrialRNXT · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name K. Angela Macfarlane; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.